Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 48
1.
Eur Rev Med Pharmacol Sci ; 25(18): 5836-5842, 2021 09.
Article En | MEDLINE | ID: mdl-34604975

OBJECTIVE: Functional gastrointestinal disorders are common gastrointestinal diseases. The pathophysiology is multifactorial and psychosocial distress worsens symptoms severity. Since the end of 2019 the world has been facing COVID-19 pandemic. The associated control measures have affected the psychological health of people. The aim of the present study is to evaluate the impact of the COVID-19 pandemic on the prevalence of functional gastrointestinal disorders among Italian children and adolescents. PATIENTS AND METHODS: The study sample is composed of 407 patients (187 males, 220 females), aged from 10 to 17 years. The mean age is 14.27 ± 2.24 years. The study was conducted through the Italian version of the Questionnaire on Pediatric Gastrointestinal Symptoms-Rome III Version.  The prevalence of each disorder has been calculated as the ratio of affected subjects for each disease and the total number of effective cases for that specific disease. RESULTS: The study demonstrates that the prevalence of Functional Gastrointestinal Disorder in Italian children, during the COVD-19 pandemic, is higher, compared with the one reported in the previous studies. The most frequent disorders are Abdominal Migraine and Irritable Bowel Syndrome. CONCLUSIONS: Our study is the first one which provides data of the prevalence of Functional gastrointestinal disorders in sample of Italian adolescents, during the COVID-19 pandemic. The study underlines the need to focus on stress management, in order to reduce the effects of the lockdown on the psychological wellness of the youngest.


COVID-19/psychology , Gastrointestinal Diseases/etiology , Gastrointestinal Diseases/psychology , Quarantine/psychology , Social Isolation/psychology , Stress, Psychological/complications , Abdominal Pain/epidemiology , Abdominal Pain/etiology , Abdominal Pain/psychology , Adolescent , Aerophagy/epidemiology , Aerophagy/etiology , Aerophagy/psychology , COVID-19/epidemiology , COVID-19/prevention & control , Child , Constipation/epidemiology , Constipation/etiology , Constipation/psychology , Dyspepsia/epidemiology , Dyspepsia/etiology , Dyspepsia/psychology , Fecal Incontinence/epidemiology , Fecal Incontinence/etiology , Fecal Incontinence/psychology , Female , Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/epidemiology , Humans , Irritable Bowel Syndrome/epidemiology , Irritable Bowel Syndrome/etiology , Irritable Bowel Syndrome/psychology , Italy , Male , Migraine Disorders/epidemiology , Migraine Disorders/etiology , Migraine Disorders/psychology , Prevalence , Rumination Syndrome/epidemiology , Rumination Syndrome/etiology , Rumination Syndrome/psychology , Stress, Psychological/diagnosis , Surveys and Questionnaires , Vomiting/epidemiology , Vomiting/etiology , Vomiting/psychology
2.
Eur Rev Med Pharmacol Sci ; 25(1): 241-249, 2021 01.
Article En | MEDLINE | ID: mdl-33506913

The prevalence of obesity continues to increase. Obesity is associated with cardiovascular risk factors: elevated blood pressure, dyslipidemia and glycemic alterations, causing metabolic syndrome. A subgroup of obese, Metabolically Healthy Obese (MHO), appears to be less prone to the development of metabolic disturbances. Carotid intima-media thickness (cIMT) is a non-invasive marker of subclinical atherosclerosis and it is associated with increased risk of CVD events. To investigate the cardiovascular risk, demonstrated through the increase of cIMT in obese subjects without Metabolic Syndrome (MetS), we have studied cIMT in MHO, metabolically unhealthy obese (MUO) and obese with MetS diagnosed with the IDEFICS criteria and compared to a control group. 224 obese children aged 6 to 21 years (13,50 ± 4.01 years) and 103 normal weight subjects aged 7 to 19 years (13.2 ± 4.1 years) were studied. The body mass index (BMI) of the obese children was ≥ the 95th percentile. Based on the IDEFICS criteria, we divided the obese subjects in three groups: MHO if no criteria were out of range, MUO if, at least, one of the criteria was out of range and MetS group if all the IDEFICS criteria were present. In all the subjects cIMT was measured with color Doppler by a vascular surgeon. Differences in the means of the variables were tested by ANOVA. Based on the IDEFICS criteria, 32 subjects were affected by MetS (14..3%), 66 were considered MUO (29.4%) and 126 MHO (56.3%). Comparison of mean cIMT highlighted a significant difference (p < 0.05) between the groups of obese children (MHO, MUO and MetS) and controls for both carotid arteries. We did not find significative difference in the value of cIMT in MHO, MUO and MetS subjects, and all groups showed cIMT value higher compared to cIMT of the controls.


Carotid Intima-Media Thickness/adverse effects , Metabolic Syndrome/metabolism , Obesity/metabolism , Adolescent , Adult , Child , Female , Humans , Male , Metabolic Syndrome/pathology , Obesity/pathology , Young Adult
3.
Epilepsy Res ; 139: 92-101, 2018 01.
Article En | MEDLINE | ID: mdl-29212048

1p36 terminal deletion is a recently recognized syndrome with multiple congenital anomalies and intellectual disability. It occurs approximately in 1 out of 5000 to 10,000 live births and is the most common subtelomeric microdeletion observed in human. Medical problems commonly caused by terminal deletions of 1p36 include developmental delay, intellectual disability, seizures, vision problems, hearing loss, short stature, brain anomalies, congenital heart defects, cardiomyopathy, renal anomalies and distinctive facial features. Although the syndrome is considered clinically recognizable, there is significant phenotypic variation among affected individuals. Genotype-phenotype correlation in this syndrome is complicated, because of the similar clinical evidence seen in patients with different deletion sizes. We review 34 scientific articles from 1996 to 2016 that described 315 patients with 1p36 delection syndrome. The aim of this review is to find a correlation between size of the 1p36-deleted segments and the neurological clinical phenotypes with the analysis of electro-clinical patterns associated with chromosomal aberrations, that is a major tool in the identification of epilepsy susceptibility genes. Our finding suggest that developmental delay and early epilepsy are frequent findings in 1p36 deletion syndrome that can contribute to a poor clinical outcome for this reason this syndrome should be searched for in patients presenting with infantile spasms associated with a hypsarrhythmic EEG, particulary if they are combined with dismorphic features, severe hypotonia and developmental delay.


Chromosome Disorders/diagnosis , Chromosome Disorders/physiopathology , Epilepsy/diagnosis , Epilepsy/physiopathology , Chromosome Deletion , Chromosomes, Human, Pair 1 , Epilepsy/genetics , Humans
5.
Ital J Pediatr ; 43(1): 27, 2017 Mar 07.
Article En | MEDLINE | ID: mdl-28270183

Obesity and headache are two highly prevalent diseases both in adults and children and they are associated with a strong personal and social impact. Many studies suggest that obesity is comorbid with headache in general, and migraine in particular and obesity seems to be a risk factor for migraine progression and for migraine frequency both in adults and in children. Research shows that there are multiple areas of overlap between migraine pathophysiology and the central and peripheral pathways regulating feeding: inflammatory mediators such as the calcitonin gene-related protein (CGRP), neurotransmitters such as serotonin, peptides such as orexin and adipocytokines such as adiponectin (ADP) and leptin could explain the common pathogenesis. In this paper we discussed the association between obesity and migraine through the analysis of the most recent studies in children and we reviewed data from literature in order to assess the association between obesity and headache and to clarify the possible common pathogenic mechanisms.


Migraine Disorders/epidemiology , Pediatric Obesity/epidemiology , Risk Assessment , Child , Comorbidity/trends , Global Health , Humans , Risk Factors
6.
Eur J Paediatr Dent ; 7(2): 67-72, 2006 Jun.
Article En | MEDLINE | ID: mdl-16842026

AIM: The relationship between bone mineral density (BMD), age and dental caries has been studied. Quantitative ultrasonography (QUS) is an economic, non invasive, and reproducible method for measuring both bone mineral density and bone elasticity in growing subjects in large populations. METHODS: This study evaluated the relationship between BMD and prevalence of dental caries (Decayed Missing Filled Tooth - DMFT) in 540 healthy adolescent with mean age 12.3 years, age range 10 to 15 years, resident in two provinces in south Italy. BMD was measured using QUS by calculating the speed of sound (m/s) on the last four fingers of the non dominant hand, with the estimate thus obtained being defined as the AD-SoS (Amplitude-Dependent Speed of Sound and categorised as AD-SoS < or = 1900 m/s and AD-SoS > 1900 m/s). Occurrence of dental caries was defined using the DMFT index (DMFT=0 and DMFT > 0). RESULTS: The results of the multifactorial analysis, carried out with logistic model, confirms the expected statistically significant association between response (DMFT) and explicative variables -- AD-SoS (P < 0.006) and Age (P < 0.004). CONCLUSION: Greater bone mineralisation (AD-SoS1900 m/s) and younger age (Age < or =12 years) are dental caries prevention factors: the probability to have caries for the subjects in such conditions is 0.34, about the half of that recorded in the subjects with lower bone mineralisation and older age (0.62).


Bone Density , Dental Caries/diagnostic imaging , Finger Phalanges/diagnostic imaging , Adolescent , Age Factors , Child , Cross-Sectional Studies , Dental Caries/physiopathology , Epidemiologic Methods , Finger Phalanges/physiopathology , Humans , Ultrasonography
7.
Ann Ital Chir ; 73(6): 631-4, 2002.
Article It | MEDLINE | ID: mdl-12820588

The authors report a case of giant fibroadenoma of the breast in a girl of 11 years old. Juvenile or giant fibroadenoma is a rare pathology usually presenting in adolescence, characterized by massive and rapid enlargement of an encapsulated mass. Nowadays there are some preoperative difficulties distinguishing it from cystosarcoma phyllodes which has a benign and malignant form. It is important to differentiate the two pathologies before operation as they have a different therapeutic approach and different follow up. The etiology is believed to be an end-organ hypersensitivity to normal levels of gonadal hormones and the age of presentation is between 10 to 18 years old. Treatment is usually surgical and ranges from simple excision to subcutaneous mastectomy with reconstruction.


Breast Neoplasms/diagnostic imaging , Fibroadenoma/diagnostic imaging , Breast Neoplasms/surgery , Child , Female , Fibroadenoma/surgery , Humans , Mammography
8.
J Endocrinol Invest ; 24(6): 438-44, 2001 Jun.
Article En | MEDLINE | ID: mdl-11434668

The current study was designed to examine the relationship between body fat distribution, as evaluated by anthropometry and magnetic resonance imaging (MRI), and circulating insulin, sex hormone and SHBG levels in obese adolescent girls. Twenty-nine obese adolescent girls, aged 12.6-16.9 years with a mean BMI of 30.51+/-1.86 participated in this study. All girls had breast stage B4-5 and pubic hair stage P4-5. Percent obesity and BMI as indices of being overweight were calculated; the waist-to-hip ratio (WHR) and the waist-to-thigh ratio (WTR) were calculated to obtain two anthropometric indices for the pattern of body fat distribution. The areas of visceral (VAT) and subcutaneous adipose tissue (SAT) were evaluated by MRI at the L4-L5 level. Serum concentrations of total T, DHEAS, 17beta-estradiol, progesterone and SHBG were measured. Plasma glucose and insulin concentrations were evaluated during an oral glucose tolerance test. WHR was the only anthropometric parameter that was significantly associated with the area of VAT. Insulin level showed correlation with both WHR and the area of VAT; no correlation was found between insulin levels and WTR. Both WHR and VAT were negatively correlated with serum DHEAS level and positively correlated with T level. There were strong negative correlations between serum SHBG level and the area of VAT and WHR. Inverse correlation was found between serum SHBG level and insulin. Serum 17beta-estradiol and progesterone levels showed no significant correlation with all the patterns of body fat distribution. SAT was not significantly correlated with both anthropometric parameters and any of the sex hormones evaluated. We can draw two main conclusions. Firstly, in massively obese adolescent girls, the WHR seems to be a good indicator for the accumulation of VAT, and abdominal obesity, rather than adiposity per se, appears to be related to biochemical complications. Secondly, increased upper body adiposity and, in particular, the intra-abdominal fat area are associated with increased insulin levels in massively obese adolescent girls. The associated reductions in SHBG and DHEAS levels represent an early general risk factor for the development of metabolic and cardiovascular diseases in this population, as previously described for obese adult women.


Adipose Tissue/physiopathology , Body Composition , Insulin/blood , Obesity/physiopathology , Adipose Tissue/pathology , Adolescent , Blood Glucose/analysis , Body Constitution , Child , Dehydroepiandrosterone Sulfate/blood , Estradiol/blood , Female , Glucose Tolerance Test , Humans , Magnetic Resonance Imaging , Obesity/pathology , Puberty , Sex Hormone-Binding Globulin/analysis , Testosterone/blood , Viscera
9.
J Pediatr Endocrinol Metab ; 13 Suppl 1: 695-701, 2000 Jul.
Article En | MEDLINE | ID: mdl-10969911

We review the etiology and age incidence of precocious puberty in 438 girls examined between 1988-1998; 428 (97.7%) had central precocious puberty (CPP), the remaining 10 (2.3%) gonadotropin-independent precocious puberty (GIPP) of ovarian origin. The majority of CPP girls (59.6%) were aged between 7-7.9 yr, 22.4% were 6 year olds, and only 18% were under 6 years old. Cranial CT and/or MRI performed in 304/428 girls, showed neurogenic abnormalities in 56/304 (18.4%) CPP girls; 30 (9.9%) were due to previously diagnosed intracranial abnormalities and the remaining 26 (8.5%) were detected at the diagnosis of CPP. The frequency of neurogenic CPP tended to be higher in girls under 4 years of age while the frequency of idiopathic CPP tended to be higher in girls aged between 7-7.9 years, but no statistically significant differences were found. Interestingly, some CNS anomalies either of tumoral or congenital origin were detected at presentation in 7% of the girls aged over 7 years. Other related or coincidental clinical anomalies, mainly due to genetic diseases, were observed in 22/304 (7.2%) patients. History of precocious maternal menarche was found in 12/304 (4%) girls. In conclusion, idiopathic CPP was observed in 74% of the girls in this study. Neurogenic anomalies or other coincidental or related clinical findings were observed in the remaining 26%. The increased frequency of idiopathic CPP in girls aged over 7 years may suggest an early, but otherwise normal onset of puberty in many of these girls as a consequence of the trend towards earlier maturation. Nonetheless, the finding of CNS anomalies also in the older patients, raises the question of whether these patients should undergo a complete diagnostic work-up.


Brain Diseases/complications , Puberty, Precocious/epidemiology , Puberty, Precocious/etiology , Abnormalities, Multiple , Age Distribution , Child , Child, Preschool , Female , Genetic Diseases, Inborn , Humans , Incidence , Italy , Magnetic Resonance Imaging , Medical Records , Puberty, Precocious/diagnosis , Puberty, Precocious/genetics , Tomography, X-Ray Computed
10.
J Chemother ; 12 Suppl 3: 17-22, 2000 Sep.
Article En | MEDLINE | ID: mdl-11432677

This study is one of the first in the literature with the aim of assessing the effectiveness of antimicrobial prophylaxis with a single preoperative dose of long-acting ceftriaxone in a retrospective analysis of 3,603 patients undergoing laparoscopic cholecystectomy. All patients who underwent laparoscopic cholecystectomy between October 1990 and December 1997 were reviewed. Antimicrobial prophylaxis with a single dose of ceftriaxone (1 g) was given intravenously at the induction of anesthesia. Patients were closely monitored for infections until 4 weeks after surgery. Postoperative infections occurred in 44 of the 3,603 patients undergoing laparoscopic cholecystectomy, with an infection rate of 1.22%. The infectious complications mainly comprised wound infections (n=13) but also included intra-abdominal abscesses (n=3), pneumonia (n=9), urinary tract infections (n=3) and other infections (n=16). The results of this retrospective and non-randomized study, show that a single-shot regimen containing ceftriaxone may be a cost-effective measure in preventing postoperative infections in patients undergoing laparoscopic cholecystectomy.


Antibiotic Prophylaxis , Ceftriaxone/therapeutic use , Cholecystectomy , Laparoscopy , Surgical Wound Infection/prevention & control , Adult , Aged , Aged, 80 and over , Antibiotic Prophylaxis/statistics & numerical data , Ceftriaxone/administration & dosage , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Italy/epidemiology , Male , Medical Records , Middle Aged , Retrospective Studies , Surgical Wound Infection/epidemiology , Treatment Outcome
11.
J Endovasc Surg ; 5(3): 206-15, 1998 Aug.
Article En | MEDLINE | ID: mdl-9761571

PURPOSE: To report the outcome of an Italian multicenter trial of endovascular abdominal aortic aneurysm (AAA) exclusion using the Stentor device. METHODS: Between April 1995 and July 1996, 66 patients (63 men; average age 69 years, range 53 to 84) with infrarenal AAAs meeting the inclusion criteria were enrolled. The average diameter of the aneurysm was 4.6 cm (range 4.2 to 7). Three (4.5%) of the 66 AAAs were anastomotic aneurysms. RESULTS: Sixteen (25%) tubular and 50 (76%) bifurcated endograft procedures were attempted; 4 (6.1%) were converted and 1 terminated owing to technical faults with the bifurcated graft's second limb. One tube graft was too short and failed to exclude an anastomotic aneurysm. Sixty (91%) endograft procedures were completed successfully. Six (9.1%) vascular complications occurred, three in one patient who subsequently died of pulmonary embolism 72 hours postoperatively (1.5% mortality). There were four (6.1%) proximal endoleaks; two sealed spontaneously in < 1 month, and a third was converted (7.6% conversion rate). The fourth is being observed. Clinical success (aneurysm exclusion with no death or endoleak) at 30 days was 86.3% (57/66). In the 23-month follow-up of 57 eligible patients, 2 patients died of unrelated causes and 1 graft limb thrombosed, requiring a crossover femoral bypass. One patient was converted to surgical repair at 5 months postoperatively when increasing aneurysm size signaled an undisclosed endoleak (1.8% late conversion rate). Five other secondary endoleaks were treated with endovascular techniques. CONCLUSIONS: The Stentor was technically feasible in 10% to 40% of AAA candidates in this study, although deployment of the second limb was problematic in the bifurcated device. Introduction of the second-generation Vanguard endograft brought this study to an end.


Aortic Aneurysm, Abdominal/surgery , Blood Vessel Prosthesis Implantation/instrumentation , Stents , Aged , Aged, 80 and over , Angiography , Aortic Aneurysm, Abdominal/diagnostic imaging , Feasibility Studies , Female , Follow-Up Studies , Humans , Incidence , Intraoperative Complications , Italy , Male , Middle Aged , Postoperative Complications/epidemiology , Retrospective Studies , Survival Rate , Tomography, X-Ray Computed , Treatment Outcome
12.
Bone Marrow Transplant ; 20(7): 567-73, 1997 Oct.
Article En | MEDLINE | ID: mdl-9337058

The aim of this study was to evaluate the treatment effects with recombinant human growth hormone (rhGH) in a group of patients after bone marrow transplantation for thalassemia major. At the end of treatment we divided the subjects into two groups according to the outcome of the therapy: responder and nonresponder. Responder group: after 24 months of rhGH administration, growth rate was still significantly higher in respect to start of treatment (P < 0.0001). Plasma levels of IGF-I rose significantly (P < 0.003). The serum levels of serum asparate aminotransferase (SGOT) and alanine aminotransferase (SGPT) were higher compared to normal values but improved in non-responder patients. There was no difference in the mean concentration of these parameters before and after treatment (P = NS). Non-responder group: these patients had a worsening of the growth rate during rhGH administration. There was no increase of the IGF-I levels. Single values of transaminase and ferritin levels were higher than in responder patients before and after treatment. There was a significant correlation between IGF-I, SGOT, SGPT and ferritin in all patients before and after therapy. It appears from these data that rhGH administration is worth serious consideration in patients after BMT for thalassemia major presenting impaired growth hormone secretion. This treatment can offer good results only in cases where the normal hepatic synthesis of IGF-I is conserved and where liver damage has not reached irreversible conditions, as we have seen in the responder group.


Bone Marrow Transplantation , Growth/drug effects , Human Growth Hormone/administration & dosage , beta-Thalassemia/physiopathology , Adolescent , Anthropometry , Child , Female , Growth/physiology , Humans , Male , Recombinant Proteins/administration & dosage , Transplantation, Homologous , beta-Thalassemia/therapy
13.
Clin Endocrinol (Oxf) ; 47(1): 61-4, 1997 Jul.
Article En | MEDLINE | ID: mdl-9302373

OBJECTIVE: It is widely accepted that arginine is a potent GH secretagogue in man, probably acting via inhibition of hypothalamic somatostatin release. Although many other amino acids are known to stimulate GH secretion, their effects and mechanisms of action have not been extensively studied in humans. The aim of the present study was to clarify the effect, if any, of methionine (MET) on GH secretion in children with normal short stature (normal height velocity and IGF-1 > 100 micrograms/l). DESIGN: We studied the effect of MET (0.2 g/kg intravenously (i.v.) over 30 min) on both basal and GHRH (1 microgram/kg i.v. at 0 min)-induced GH secretion (group A) comparing its effect with that of arginine (ARG) at low and classical doses 0.2 and 0.5 g/kg i.v. over 30 min) (groups B and C). The effect of the combined administration of MET and ARG (0.5 g/kg i.v. over e0 min) (group D) on GH secretion was also studied. PATIENTS: Thirty-four children (20 male and 14 female, age 12.8-14.0 years), divided into four groups. MEASUREMENTS: Serum Gh was measured in duplicate by immunoradiometric assay. RESULTS: In group A, MET increased basal Gh levels (peak, mean +/- SEM 14.6 +/- 2.6 vs 2.6 +/- 0.6 mU/l; P < 0.01) and potentiated the GH response to 1 microgram/kg i.v. GHRH (78.0 +/- 17.6 vs 41.6 +/0 9.8 mU/I; P < 0.02). In group B, ARG (0.2 g/kg) increased basal GH levels (16.2 +/- 5.2 vs 2.4 +/- 0.6 mU/I; P < 0.03) and potentiated the GH response to GHRH (119.6 +/- 20.4 vs 48.8 +/- 14.2 mU/I; P < 0.01). In group C, ARG (0.5 g/kg) induced a clear GH rise (28.0 +/- 3.8 vs 2.0 +/- 0.6 mU/I; P < 0.001) and potentiated the GH response to GHRH (93.4 +/- 10.0 vs 34.2 +/- 4.6 mU/I; P < 0.001). The GH responses to MET and ARG alone in groups A and B were similar and lower than that to ARG in group C. The GH responses to MET or ARG combined with GHRH in groups A, B and C were similar. In group D MET failed to modify the GH response to 0.5 g/kg i.v. ARG (10.8 +/- 6.4 vs 9.6 +/- 6.0 mU/I). CONCLUSION: Methionine potentiates both basal and GHRH-induced Gh secretion in children as effectively as arginine. As methionine has no interaction with arginine, our data suggest that these amino acids act via a common mechanism.


Growth Disorders/drug therapy , Growth Hormone-Releasing Hormone/therapeutic use , Growth Hormone/metabolism , Methionine/therapeutic use , Adolescent , Arginine/therapeutic use , Child , Drug Synergism , Drug Therapy, Combination , Female , Growth Disorders/blood , Growth Disorders/physiopathology , Growth Hormone/blood , Humans , Immunoradiometric Assay , Male
14.
J Clin Endocrinol Metab ; 82(3): 861-4, 1997 Mar.
Article En | MEDLINE | ID: mdl-9062497

We studied the variability of the GH response to the synthetic hexapeptide hexarelin (Hex) and the effect of sex steroids on the GH-releasing effect of Hex in a group of prepubertal short normal children. Twenty-five children were tested on two occasions 3-7 days apart with 2 micrograms/kg, i.v., Hex. The GH response to Hex was reevaluated after testosterone (T) administration in 10 boys, after ethinyl estradiol (EE) administration in 15 children (5 boys and 10 girls), and after oxandrolone (Ox) administration in 8 boys. In the 25 children tested twice, the mean GH peak and mean area under the curve after the first and second tests were similar. The mean (+/- SD) coefficients of variation of the GH peak and area under the curve responses to Hex was 22.7 +/- 21.0% and 24.0 +/- 20.7%, respectively. Priming with T and EE resulted in an increased GH response to Hex [41.8 +/- 21.0 before vs. 71.1 +/- 28.3 after T (P < 0.001); 43.0 +/- 14.5 before vs. 60.0 +/- 20.0 after EE (P < 0.005)], whereas Ox administration had no effect on the Hex-induced GH release. These data confirm that Hex is a potent stimulus for GH secretion in children with a limited intraindividual variability. In addition, we have shown that both T and EE, but not Ox, significantly augment the GH-releasing effect of Hex. Our data suggest that the sex steroid-induced increase in the GH response to Hex is mediated by estrogens.


Ethinyl Estradiol/pharmacology , Human Growth Hormone/blood , Oligopeptides/pharmacology , Oxandrolone/pharmacology , Testosterone/pharmacology , Adolescent , Body Height , Child , Female , Humans , Male , Reproducibility of Results
15.
Surg Endosc ; 10(9): 875-9, 1996 Sep.
Article En | MEDLINE | ID: mdl-8703141

BACKGROUND: The aim of the present study was to evaluate retrospectively the experience of six surgical units currently performing laparoscopic colorectal surgery. METHODS: From November 1991 to January 1994, 200 patients (103 male, 97 female; mean age 62.5 years) were candidates for, and received, laparoscopic colorectal resection for benign (54) or malignant (196) lesions. All the units excluded patients with locally advanced organ tumors and all cases with suspected perforation and ascites. One center submitted to laparoscopic resection only stage I and IV adenocarcinoma. All surgeons considered obesity a relative contraindication. The following data were analyzed: indications, conversion rate to open surgery, operative time, morbidity and mortality, resumption of gastrointestinal function, number of lymph nodes harvested, hospital stay. RESULTS: Twenty-one out of 200 patients were converted to open surgery (10.5%); 37 patients had a complete laparoscopic procedure (17.1%); 137 had an assisted resection (68.5%); and the remaining 5 patients had a facilitated resection. The mean operative time was 208 min (90-480) for assisted resection and 275 min (54-550) for complete laparoscopic resection. The mortality rate was 1.7%; the overall morbidity was 19.6% (major complications 11.2%). All patients quickly became ambulatory and showed a prompt resumption of gastrointestinal functions, and less postoperative pain if compared with converted cases. The average number of lymph nodes was 12.1 (range 1-32). The mean hospital stay was 8.6 days (range 5-14.5). The mean follow-up was 16 months (range 6-24). The recurrence rate 11.7%. CONCLUSIONS: Laparoscopy seems to offer the possibility of minimally invasive treatment, but long-term follow-up is needed to evaluate the efficacy of laparoscopic surgery in the treatment of colorectal cancer.


Colectomy/methods , Colonic Neoplasms/surgery , Laparoscopy , Rectal Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Treatment Outcome
16.
Int J Obes Relat Metab Disord ; 19(12): 851-7, 1995 Dec.
Article En | MEDLINE | ID: mdl-8963351

OBJECTIVE: To compare the growth charts of obese subjects (4-18 years) with the Tanner's growth curves and to analyze the growth velocities and bone age of obese children in prepuberty and adolescence. Moreover to compare the relationship between the serum insulinemic and glycemic levels and height standard deviation score (HSDS). DESIGN: Growth charts: this study included 1250 obese subjects (669 males, 581 females) observed between 1981 and 1993 and divided into seven age categories (4-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18 years). Growth velocities: yearly growth velocities of 579 obese subjects (325 males, 254 females) were compared to growth velocities of 473 controlled children of the same sex, chronological age and pubertal stage. Bone age (BA) of 846 obese subjects (470 males, 376 females) was estimated. Blood analysis: insulin secretion of 70 obese children was considered and compared to 70 lean controls of equal chronological age and sex. MEASUREMENTS: Growth rate, standardized height and other physical characteristics of the children were measured by trained examiners. All subjects were evaluated singularly for at least 4 years with a follow-up every 6 months. BA was estimated by radiograph of the left hand and wrist using the Tanner-Whitehouse II system by a single observer. For the insulin secretion study and glycemic levels oral glucose tolerance test (OGTT) was performed using a glucose load of 1.75 g/kg per body weight. Plasma insulin was assessed by a double antibody radioimmunoassay. RESULTS: In adipose children the growth charts, referred to 97th centile, 50th centile and 3rd centile, were superior to those of the normal population up to the age of 13 and 12.5 years for male and for female respectively; growth decreases at the above age in both sexes. The obese subjects were equal in height to the non obese subjects as they reached their 18th birthday. The growth velocity (cm/yr) of the obese child, in the age range considered here, does not show differences when compared with the lean child in the prepubertal status (P not significant) but decreases during Tanner's stage II, III IV in boys and girls (P < 0.0001). BA is more advanced over chronological age (delta BA-CA) in both sexes. The increase of BA over CA does not show a remarkable difference during pubertal maturation in boys (P not significant); whereas in girls the delta BA-CA decreases with advancing sexual maturation (P < 0.0001). Our obese subjects have significantly higher plasma insulinemic levels compared with the lean controls (P < 0.0001). Moreover there is a positive correlation between plasma insulinemic levels and HSDS (r = 0.881, P < 0.0001). We did not observe a correlation between serum glycemic levels and HSDS. CONCLUSION: Our data demonstrate that the growth increase in an obese child starts in the first years of life. The statural advantage acquired in the first years of life would be exploited and maintained up to the beginning of puberty and with a growth velocity equal to that of the lean subject. Skeletal maturation is strongly increased in both sexes. Bone age remained advanced during the entire period of pubertal development. During puberty obese subjects demonstrate a less notable growth spurt when compared with lean subjects. The growth advantage gradually decreases and final adult height of obese and normal subjects is equal.


Bone Development/physiology , Growth/physiology , Obesity/physiopathology , Adolescent , Aging/physiology , Blood Glucose/analysis , Bone and Bones/diagnostic imaging , Bone and Bones/pathology , Bone and Bones/physiology , Child , Child, Preschool , Female , Glucose Tolerance Test , Humans , Hyperinsulinism/blood , Hyperinsulinism/metabolism , Hyperinsulinism/physiopathology , Insulin/blood , Male , Obesity/blood , Obesity/pathology , Radiography , Radioimmunoassay , Time Factors
17.
Surg Laparosc Endosc ; 5(5): 354-8, 1995 Oct.
Article En | MEDLINE | ID: mdl-8845978

We report our first experience with a laparoscopic treatment of congenital choledochal cysts involving the total cyst resection and the reconstruction of the biliary and gastrointestinal tracts through a transmesocolic hepatic-jejunal Roux-en-Y loop anastomosis. The procedure was carried out in a 14-kg 6-year-old girl with a congenital choledochal cyst of the first type, according to the Alonso-Lej classification. The cyst was divided using a Multifire EndoGIA 30 stapler. Hepatic-jejunal and jejunojejunal anastomoses were made with 4.0 chrome catgut interrupted sutures. Intestinal recanalization occurred on the 2nd postoperative day and the postoperative course was uneventful. The laparoscopic approach affords several advantages: excellent intraoperative visualization of tiny structures and, therefore, great surgical accuracy; early resumption of peristalsis; no postoperative pain; no laparocele; prevention of adhesions; excellent esthetics; and quicker resumption of school and sports activities.


Choledochal Cyst/surgery , Laparoscopes , Video Recording/instrumentation , Anastomosis, Roux-en-Y/instrumentation , Anastomosis, Surgical/instrumentation , Child , Female , Humans , Jejunum/surgery , Liver Function Tests , Postoperative Complications/etiology , Surgical Staplers , Suture Techniques/instrumentation
18.
Bone Marrow Transplant ; 15(2): 227-33, 1995 Feb.
Article En | MEDLINE | ID: mdl-7773211

Twenty two patients with thalassemia major who received successful bone marrow transplantation (BMT) were followed to verify the impact of the transplant procedure on subsequent growth and development. The transplant preparative regimen consisted of busulphan and cyclophosphamide. Growth and endocrinological function were assessed during the first 4 years following BMT. At the time of transplant most patients showed growth retardation. The median difference between chronological age and bone age was -9.5 months for the boys and -8.5 months for the girls. Patients > 7 years old at the time of BMT showed a significant worsening of their growth delay at 48 months following BMT compared with 12 months before transplantation. Patients < 7 years at the time of BMT had their growth retardation constant over time span after transplantation. Moreover six of 11 younger patients showed an improvement of their growth delay compared with one of 11 older patients. The outcome of height standard deviation score at 24 and 48 months following BMT was strictly correlated with the level of serum transaminases and ferritin. Sixteen patients had impaired growth hormone secretion after a provocative test evaluated at 24 months after transplant. At 48 months there was no significant increase in the mean peak GH levels. This study confirms that the growth retardation of patients with thalassemia major is multifactorial.


Bone Marrow Transplantation/physiology , Child Development/physiology , Growth , Thalassemia/surgery , Adolescent , Anthropometry , Bone Marrow Transplantation/adverse effects , Child , Child, Preschool , Female , Hormones/blood , Humans , Infant , Intellectual Disability/etiology , Male , Puberty , Thalassemia/complications , Thalassemia/physiopathology , Thyroid Gland/metabolism
19.
Chir Ital ; 47(1): 24-43, 1995.
Article It | MEDLINE | ID: mdl-8706183

The authors describe the technique for the treatment of gallbladder stones using a laparoscopic approach and discuss the diagnostic and operative flow chart stressing complications and ways to avoid them. A total of 2517 non-selected patients underwent surgery since october 1990 up to september 1995. 252 were affected by acute cholecystitis (10%); 172 underwent emergency laparoscopic cholecystectomy. ERCP was performed in 278 patients (11.04%): 177 underwent endoscopic sphincterotomy and laparoscopic cholecystectomy, 21 underwent laparoscopic cholecystectomy before sphincterotomy, 8 laparoscopic cholecystectomy and ESWL. Laparoscopic cholecystectomy was converted into laparotomy in 37 patients (1.4%); surgery was abandoned in 3 patients following to onset of intense bradycardia. Major complications were observed in 0.63%; bile duct injury occurred in four patients (0.15%). One patient died following a massive intraoperative myocardial infarction. Average operative time was 21 minutes. Only 22.8% of patients required mild analgesia on the first day after surgery. The average hospital postoperative stay was 2.6 days. Return to work took place in 98% of non complicated patients within one week of being discharged from hospital.


Cholecystectomy, Laparoscopic , Cholelithiasis/surgery , Cholecystectomy, Laparoscopic/adverse effects , Cholecystectomy, Laparoscopic/instrumentation , Cholecystectomy, Laparoscopic/methods , Cholecystectomy, Laparoscopic/standards , Female , Humans , Pregnancy , Pregnancy Complications/surgery
20.
Minerva Pediatr ; 46(7-8): 347-50, 1994.
Article It | MEDLINE | ID: mdl-7935253

The effect of growth hormone (GH) treatment in non-GH deficient subjects has been amply studied over the past few years. Although the results of these studies are encouraging, there are still no definitive data since the findings are not comparable due to the different characteristics of the populations examined. In the present study the authors examined the following parameters: stature, height SDS, growth rate, bone age and final height prediction according to Tanner, pubertal stage, before and after treatment with biosynthetic GH at a dose of 1.4 IU/kg of bodyweight for 12 months. The population treated consisted of 10 subjects (5 males and 5 females) aged between 7.3 and 9.5 years old, all prepubertal, with "familial short stature", selected according to the following criteria: stature below the 3rd centile, normal growth rate, normal GH response to stimuli using clonidine and insulin, correlation with parental stature between 25th and 75th centile, bone age correlated to chronological age, absence of other pathologies. After 12 months height SDS moved from -2.75 +/- 0.26 to -2.23 +/- 0.25 (p < 0.5); the growth rate changed from 5.75 +/- 0.63 to 6.66 +/- 0.56 (p < 0.05). No abnormal acceleration of bone age as observed: it moved from 8.2 +/- 0.62 to 9.5 +/- 0.72; all subjects continued to be prepubertal. The expected final stature changed from 154 +/- 2.38 to 159 +/- 0.7 (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)


Dwarfism, Pituitary/drug therapy , Growth Hormone/administration & dosage , Age Determination by Skeleton , Body Height/drug effects , Child , Drug Evaluation , Dwarfism, Pituitary/diagnosis , Dwarfism, Pituitary/genetics , Female , Growth/drug effects , Humans , Male , Time Factors
...